Skip to content

Agios Pharmaceuticals AGIO Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Incyte logo
IncyteINCY
Disc Medicine logo
Disc MedicineIRON
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
Enterprise value$2.04B+15.2%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's accrued liabilities, current?
Agios Pharmaceuticals (AGIO) reported accrued liabilities, current of $26.29M in Q1 2026.
How has Agios Pharmaceuticals's accrued liabilities, current changed year-over-year?
Agios Pharmaceuticals's accrued liabilities, current increased by 26.6% year-over-year, from $20.76M to $26.29M.
What is the long-term trend for Agios Pharmaceuticals's accrued liabilities, current?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's accrued liabilities, current has grown at a 8.1% compound annual growth rate (CAGR), from $30.8M to $45.46M.